SEC Form 4 · accession 0001213900-18-001247
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nadav Kidron
Officer — President and CEO · Director · 10% Owner
Period of report
Jan 31, 2018
Accepted (ET)
Feb 2, 2018 · 5:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $8.14 | Jan 31, 2018 | A | 97,000 | A | — | Jan 31, 2028 | Common Stock | 97,000 | 97,000 | D |
Explanation of responses
- F1The Stock Option will vest in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022.